Levit Use In Pregnancy & Lactation

Fertility: No impact on fertility was detected in animal studies. No clinical data are available, potential risk for human is unknown.
Pregnancy: Levetiracetam is not recommended during pregnancy and in women of childbearing potential not using contraception unless clearly necessary. There are no adequate data available from the use of levetiracetam in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for human is unknown. As with other antiepileptic medicinal products, physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentration has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with levetiracetam should be ensured. Discontinuation of antiepileptic treatment may result in exacerbation of the disease which could be harmful to the mother and the fetus.
Lactation: Levetiracetam is excreted in human breast milk. Therefore, breastfeeding is not recommended. However, if levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding.